Adaptimmune funded through to late 2019

Following share offerings in March and April that raised a net $103.2 million, Adaptimmune Therapeutics Plc has sufficient liquidity to fund operations through to late 2019, according to the company’s first-quarter results.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom